Weight & Metabolic Health
Modern options, clearly explained.
Learn how today’s metabolic peptides work, where FDA-approved uses exist, and which compounds remain investigational.
Semaglutide
A GLP-1 receptor agonist used in FDA-approved medicines for type 2 diabetes and chronic weight management. Compounded versions are not FDA-approved and require individualized clinical review.
Tirzepatide
A dual GIP/GLP-1 receptor agonist used in FDA-approved medicines for type 2 diabetes and chronic weight management. Compounded versions are not FDA-approved.
Cagrilintide
A long-acting amylin analogue being studied for weight management. It is not FDA-approved, and FDA states it cannot be used in compounding under federal law.
Retatrutide
A triple GIP/GLP-1/glucagon receptor agonist being studied for metabolic disease. It is not FDA-approved, and FDA states it cannot be used in compounding under federal law.
Educational information only. Treatment requires licensed-clinician evaluation. Availability, eligibility, risks, and benefits vary by patient and applicable law.